170 related articles for article (PubMed ID: 35701472)
1. Altered cytoskeletal status in the transition from proneural to mesenchymal glioblastoma subtypes.
Keller M; Blom M; Conze LL; Guo M; Hägerstrand D; Aspenström P
Sci Rep; 2022 Jun; 12(1):9838. PubMed ID: 35701472
[TBL] [Abstract][Full Text] [Related]
2. Current Insights into Mesenchymal Signatures in Glioblastoma.
Matsumoto Y; Ichikawa T; Kurozumi K; Date I
Acta Med Okayama; 2022 Oct; 76(5):489-502. PubMed ID: 36352795
[TBL] [Abstract][Full Text] [Related]
3. SFRP2 induces a mesenchymal subtype transition by suppression of SOX2 in glioblastoma.
Guo M; Goudarzi KM; Abedi S; Pieber M; Sjöberg E; Behnan J; Zhang XM; Harris RA; Bartek J; Lindström MS; Nistér M; Hägerstrand D
Oncogene; 2021 Aug; 40(32):5066-5080. PubMed ID: 34021259
[TBL] [Abstract][Full Text] [Related]
4. Molecular heterogeneity in a patient-derived glioblastoma xenoline is regulated by different cancer stem cell populations.
Garner JM; Ellison DW; Finkelstein D; Ganguly D; Du Z; Sims M; Yang CH; Interiano RB; Davidoff AM; Pfeffer LM
PLoS One; 2015; 10(5):e0125838. PubMed ID: 25955030
[TBL] [Abstract][Full Text] [Related]
5. New insights for precision treatment of glioblastoma from analysis of single-cell lncRNA expression.
Meng Q; Zhang Y; Li G; Li Y; Xie H; Chen X
J Cancer Res Clin Oncol; 2021 Jul; 147(7):1881-1895. PubMed ID: 33693962
[TBL] [Abstract][Full Text] [Related]
6. Detection of proneural/mesenchymal marker expression in glioblastoma: temporospatial dynamics and association with chromatin-modifying gene expression.
Murata H; Yoshimoto K; Hatae R; Akagi Y; Mizoguchi M; Hata N; Kuga D; Nakamizo A; Amano T; Sayama T; Iihara K
J Neurooncol; 2015 Oct; 125(1):33-41. PubMed ID: 26272600
[TBL] [Abstract][Full Text] [Related]
7. Increased LGALS3 expression independently predicts shorter overall survival in patients with the proneural subtype of glioblastoma.
He X; Zhang S; Chen J; Li D
Cancer Med; 2019 May; 8(5):2031-2040. PubMed ID: 30848102
[TBL] [Abstract][Full Text] [Related]
8. Formin-like 1 (FMNL1) Is Associated with Glioblastoma Multiforme Mesenchymal Subtype and Independently Predicts Poor Prognosis.
Higa N; Shinsato Y; Kamil M; Hirano T; Takajo T; Shimokawa M; Minami K; Yamamoto M; Kawahara K; Yonezawa H; Hirano H; Furukawa T; Yoshimoto K; Arita K
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31861134
[TBL] [Abstract][Full Text] [Related]
9. Silencing LncRNA LOXL1-AS1 attenuates mesenchymal characteristics of glioblastoma via NF-κB pathway.
Wang H; Li L; Yin L
Biochem Biophys Res Commun; 2018 Jun; 500(2):518-524. PubMed ID: 29678575
[TBL] [Abstract][Full Text] [Related]
10. Dissecting inherent intratumor heterogeneity in patient-derived glioblastoma culture models.
Teng J; da Hora CC; Kantar RS; Nakano I; Wakimoto H; Batchelor TT; Chiocca EA; Badr CE; Tannous BA
Neuro Oncol; 2017 Jun; 19(6):820-832. PubMed ID: 28062830
[TBL] [Abstract][Full Text] [Related]
11. Mesenchymal and Proneural Subtypes of Glioblastoma Disclose Branching Based on GSC Associated Signature.
Steponaitis G; Tamasauskas A
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34066996
[TBL] [Abstract][Full Text] [Related]
12. Proneural-Mesenchymal Transition: Phenotypic Plasticity to Acquire Multitherapy Resistance in Glioblastoma.
Fedele M; Cerchia L; Pegoraro S; Sgarra R; Manfioletti G
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31167470
[TBL] [Abstract][Full Text] [Related]
13. Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy.
Carrato C; Alameda F; Esteve-Codina A; Pineda E; Arpí O; Martinez-García M; Mallo M; Gut M; Lopez-Martos R; Barco SD; Ribalta T; Capellades J; Puig J; Gallego O; Mesia C; Muñoz-Marmol AM; Archilla I; Arumí M; Blanc JM; Bellosillo B; Menendez S; Esteve A; Bagué S; Hernandez A; Craven-Bartle J; Fuentes R; Vidal N; Aldecoa I; Iglesia N; Balana C
Clin Cancer Res; 2020 Dec; 26(24):6600-6609. PubMed ID: 32998960
[TBL] [Abstract][Full Text] [Related]
14. The landscape of the mesenchymal signature in brain tumours.
Behnan J; Finocchiaro G; Hanna G
Brain; 2019 Apr; 142(4):847-866. PubMed ID: 30946477
[TBL] [Abstract][Full Text] [Related]
15. Histologically defined intratumoral sequencing uncovers evolutionary cues into conserved molecular events driving gliomagenesis.
Prabhu A; Kesarwani P; Kant S; Graham SF; Chinnaiyan P
Neuro Oncol; 2017 Nov; 19(12):1599-1606. PubMed ID: 28541485
[TBL] [Abstract][Full Text] [Related]
16. Expression and prognostic significance of TCTN1 in human glioblastoma.
Meng D; Chen Y; Zhao Y; Wang J; Yun D; Yang S; Chen J; Chen H; Lu D
J Transl Med; 2014 Oct; 12():288. PubMed ID: 25304031
[TBL] [Abstract][Full Text] [Related]
17. Bivalent Chromatin Domains in Glioblastoma Reveal a Subtype-Specific Signature of Glioma Stem Cells.
Hall AW; Battenhouse AM; Shivram H; Morris AR; Cowperthwaite MC; Shpak M; Iyer VR
Cancer Res; 2018 May; 78(10):2463-2474. PubMed ID: 29549165
[TBL] [Abstract][Full Text] [Related]
18. miR-181d/MALT1 regulatory axis attenuates mesenchymal phenotype through NF-κB pathways in glioblastoma.
Yang F; Liu X; Liu Y; Liu Y; Zhang C; Wang Z; Jiang T; Wang Y
Cancer Lett; 2017 Jun; 396():1-9. PubMed ID: 28286260
[TBL] [Abstract][Full Text] [Related]
19. Mir-21-Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact.
Sathyan P; Zinn PO; Marisetty AL; Liu B; Kamal MM; Singh SK; Bady P; Lu L; Wani KM; Veo BL; Gumin J; Kassem DH; Robinson F; Weng C; Baladandayuthapani V; Suki D; Colman H; Bhat KP; Sulman EP; Aldape K; Colen RR; Verhaak RG; Lu Z; Fuller GN; Huang S; Lang FF; Sawaya R; Hegi M; Majumder S
J Neurosci; 2015 Nov; 35(45):15097-112. PubMed ID: 26558781
[TBL] [Abstract][Full Text] [Related]
20. JUN activation modulates chromatin accessibility to drive TNFα-induced mesenchymal transition in glioblastoma.
Lv X; Li Q; Liu H; Gong M; Zhao Y; Hu J; Wu F; Wu X
J Cell Mol Med; 2022 Aug; 26(16):4602-4612. PubMed ID: 35851726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
